111, Inc. Announces First Quarter 2022 Unaudited Financial Results

SHANGHAI,June 16,2022 -- 111,Inc. ("111" or the "Company") (NASDAQ: YI),a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China,today announced its unaudited financial results for the first quarter ended March 31,2022.

First Quarter 2022 Highlights

Net revenues wereRMB2.98 billion(US$470.5 million),representing an increase of 14.9% year-over-year.

Gross segment profit (1) increased by 66.3% year-over-year,with B2B segment profit increasing by 90.7% year-over-year.

Total operating expenses wereRMB294.7 million(US$46.5 million),compared to RMB289.0 million in the same quarter of last year. As a percentage of net revenues,total operating expenses decreased to 9.9% from 11.1% in the same quarter of last year,which reflected continuous improvement in our operation efficiency.

Non-GAAP loss from operations (2)wasRMB72.4 million(US$11.4 million),compared toRMB135.9millionin the same quarter of last year. As a percentage of net revenues,non-GAAP loss from operations decreased to 2.4% from 5.2% in the same quarter of last year.

Number of partnerships with pharmaceutical companies increased to 550.

(1) Gross segment profit represents net revenues less cost of goods sold.

(2) Non-GAAP loss from operations represents loss from operations excluding share-based compensation expenses.

Mr. Junling Liu,Co-Founder,Chairman,and Chief Executive Officer of 111,commented,"Despite all the challenges from pandemic lock-down in various parts of the country,we continued to grow our top line and gross segment profit in the first quarter of 2022,which brought us another step closer to profitability. Net revenue increased by 14.9% year-over-year to RMB 2.98 billion,marking the 15th consecutive quarter of year-over-year growth for 111 since our NASDAQ IPO. The B2B segment achieved year-over-year revenue and segment profit increases by 17.0% and 90.7%,respectively. Our partnerships with pharmaceutical companies continued to grow and the direct purchase relationship totaled over 550 by the end of March 2022. Our market coverage from both upstream and downstream is increasing and customer loyalty continues to grow."

Mr. Liu added,"In addition to topline growth,our gross segment profit grew 4.4 times as fast as our revenue in the first quarter. Gross segment profit grew by 66.3% year-over-year,and as a percentage of net revenues,our gross segment margins(3) improved to 6.5% as compared to 4.5% in the same quarter of last year. We are especially pleased with the margin improvement for the B2B segment,which as a percentage of net revenues,grew from 3.6% in the first quarter of 2021 to 5.9% in in the first quarter this year. Our operation efficiency also improved and total operating expenses as a percentage of net revenues decreased to 9.9% in this quarter as compared to 11.1% in the same quarter of last year. We expect this momentum in improving operation efficiency to continue as we scale,putting us on a clear path to profitability. As a result,non-GAAP loss from operation as a percentage of net revenues decreased from 5.2% in the first quarter of 2021 to 2.4% in the first quarter this year."

"We will continue to flawlessly execute our growth strategy and we are committed to steadily expand our revenue and gross segment profit. We remain resolute on our goal to reach quarterly break-even at the non-GAAP operating income level in 2022."

(3) Gross segment margin represents gross segment profit divided by net revenues.

First Quarter 2022 Financial Results

Net revenueswereRMB2.98 billion(US$470.5 million),representing an increase of 14.9% fromRMB2.59 billionin the same quarter of last year.

(In thousands RMB)

For the three months ended March31,

2021

2022

YoY

B2B Net Revenue

Product

2,440,504

2,851,396

16.8%

Service

12,025

18,360

52.7%

Sub-Total

2,452,529

2,869,756

17.0%

Cost of Products Sold(4)

2,364,354

2,701,643

14.3%

Segment Profit

88,175

168,113

90.7%

Segment Profit %

3.6%

5.9%

(In thousands RMB)

For the three months ended March31,

2021

2022

YoY

B2C Net Revenue

Product

137,150

102,131

-25.5%

Service

5,063

10,704

111.4%

Sub-Total

142,213

112,835

-20.7%

Cost of Products Sold(4)

114,618

88,413

-22.9%

Segment Profit

27,595

24,422

-11.5%

Segment Profit %

19.4%

21.6%

GrossSegment Profit

115,770

192,535

66.3%

(4) For segment reporting purposes,purchase rebates are allocated to the B2B segment and B2C segments primarily based on the amount of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as shipping and handling expense,payroll and benefits of logistic staff,logistic centers rental expenses and depreciation expenses,which are recorded in the fulfillment expenses. Cost of service revenue is recorded in the operating expense.

Operating costs and expenseswereRMB3.1 billion(US$486.6million),representing an increase of 11.5% fromRMB2.8 billionin the same quarter of last year.

Cost of products soldwasRMB2.8 billion(US$440.1 million),representing an increase of 12.5% fromRMB2.5 billionin the same quarter of last year. The increase was in line with the revenue growth.

Fulfillment expenseswereRMB94.5 million(US$14.9 million),representing an increase of 42.7% fromRMB66.3 millionin the same quarter of last year. Fulfillment expenses accounted for 3.2% of net revenues this quarter as compared to 2.6% in the same quarter of last year. The increase was mainly attributable to our investment to expand the capacity of our fulfillment centers to support future growth. The pandemic lock-down in various parts of the country also temporarily caused increases in delivery costs.

Selling and marketing expenseswereRMB114.8 million(US$18.1 million),representing a decrease of 6.2% fromRMB122.4 millionin the same quarter of last year. As a percentage of net revenues,selling and marketing expense further reduced to 3.9% in the quarter from 4.7% in the same quarter of last year.

General and administrative expenseswereRMB48.0 million(US$7.6million),representing a decrease of 7.9% fromRMB52.1 millionin the same quarter of last year. As a percentage of net revenues,general and administrative expenses accounted for 1.6% in the quarter as compared to 2.0% in the same quarter of last year.

Technology expenseswereRMB39.0 million(US$6.2 million),compared withRMB49.7 millionin the same quarter of last year. As a percentage of net revenues,technology expenses accounted for 1.3% this quarter as compared to 1.9% in the same quarter of last year.

Loss from operationswasRMB102.2million(US$16.1 million),compared toRMB173.3 millionin the same quarter of last year. As a percentage of net revenues,loss from operations decreased to 3.4% in the quarter from 6.7% in the same quarter of last year.

Non-GAAP loss from operationswasRMB72.4million(US$11.4 million),non-GAAP loss from operations decreased to 2.4% in the quarter from 5.2% in the same quarter of last year.

Net losswasRMB101.0 million(US$15.9 million),compared toRMB169.5 millionin the same quarter of last year. As a percentage of net revenues,net loss decreased to 3.4% in the quarter from 6.5% in same quarter of last year.

Non-GAAP net loss (5)wasRMB71.2 million(US$11.2 million),compared toRMB132.1 millionin the same quarter of last year. As a percentage of net revenues,non-GAAP net loss decreased to 2.4% in the quarter from 5.1% in same quarter of last year.

Net loss attributable to ordinary shareholderswasRMB110.3million(US$17.4 million),compared toRMB146.6 millionin the same quarter of last year. As a percentage of net revenues,net loss attributable to ordinary shareholders decreased to 3.7% in the quarter from 5.7% in same quarter of last year.

Non-GAAP net loss attributable to ordinary shareholders (6)was RMB80.6 million (US$12.7 million),compared to RMB109.3 million in the same quarter of last year. As a percentage of net revenues,non-GAAP net loss attributable to ordinary shareholders decreased to 2.7% in the quarter from 4.2% in same quarter of last year.

(5) Non-GAAP net loss represents net loss excluding share-based compensation expenses,net of tax. Considering the impact of accretion of redeemable non-controlling interest for the first quarter 2022 (which pertains to the Group's obligation to redeem equity interests held by certain minority investors of a subsidiary of the Company),non-GAAP net loss is used as a meaningful measurement of the operation performance of the Company.

(6) Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation expenses,net of tax.

As of March 31,2022,the Company has cash and cash equivalents,restricted cash and short-term investments of RMB901.4 million (US$142.2million),compared to RMB943.2 million as of December 31,2021.

Conference Call

111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday,2022 (7:30 PM Beijing Time on the same day).

Details for the conference call are as follows:

Event Title: 111,Inc. First Quarter 2022 Unaudited Financial Results

Registration Link: http://apac.directeventreg.com/registration/event/5728866

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering,each participant will receive a set of participant dial-in numbers,the Direct Event passcode,and a unique Registration ID,which can be used to join the conference call.

Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

A telephone replay of the call will be available after the conclusion of the conference call until June 24,9:59 ET on:

United States: +1-855-452-5696

International: +61-2-8199-0299

Conference ID: 5728866

A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/a246si8g.

Use of Non-GAAP Financial Measures

In evaluating the business,the Company considers and uses non-GAAP loss from operations,non-GAAP net loss,non-GAAP net loss attributable to ordinary shareholders,and non-GAAP loss per ADS,as supplemental measures to review and assess its operating performance. The Company defines non-GAAP loss from operations as loss from operations excluding share-based compensation expenses. The Company defines non-GAAP net loss as net loss excluding share-based compensation expenses,net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses,net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses,net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.

The Company believes that non-GAAP loss from operations,and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in loss from operations and net loss. Share-based compensation expenses is a non-cash expense that varies from period to period. As a result,management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company's core operating performance,in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP loss from operations,and non-GAAP loss per ADS provide useful information about its operating results,enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP loss from operations,or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company's operations. Further,the non-GAAP financial measures may differ from the non-GAAP information used by other companies,including peer companies,and therefore their comparability may be limited.

The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures,all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release.

Exchange Rate Information Statement

This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted,all translations from RMB to U.S. dollars are made at a rate of RMB6.3393 to US$1.00,the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of March 31,2022.

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934,as amended,and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things,the Business Outlook and quotations from management in this announcement,as well as 111's strategic and operational plans,contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission,in its annual report to shareholders,in press releases and other written materials and in oral statements made by its officers,directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks,uncertainties and other factors,all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks,uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include,but are not limited to,uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements,its ability to compete effectively in the evolving PRC general health and wellness market,its ability to manage the growth of its business and expansion plans,its ability to achieve or maintain profitability in the future,its ability to control the risks associated with its pharmaceutical retail and wholesale businesses,and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market,including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks,uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release,and 111 does not undertake any obligation to update any forward-looking statement as a result of new information,future events or otherwise,except as required under applicable law.

About 111,Inc.

111,Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy,1 Pharmacy,and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital,1 Clinic,which provides consumers with cost-effective and convenient online consultation,electronic prescription service,and patient management service. In addition,the Company's online platform,1 Medicine,serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China,111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners,which includes services such as digital marketing,patient education,data analytics,and pricing monitoring.

For more information on 111,please visit: http://ir.111.com.cn/.

For more information,please contact:

111,Inc.

Investor Relations

Email: ir@111.com.cn

111,Inc.

Media Relations

Email: press@111.com.cn

Phone: +86-021-2053 6666 (China)

111,Inc.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands,except for share and per share data)

As of

As of

December

31,2021

March 31,2022

ASSETS

RMB

RMB

US$

Current Assets:

Cash and cash equivalents

661,390

650,693

102,644

Restricted cash

99,282

99,144

15,640

Short-term investments

182,556

151,578

23,911

Accounts receivable,net

404,469

378,994

59,785

Notes Receivable

90,734

44,179

6,969

Inventories

1,121,107

1,097,851

173,182

Prepayments and other current assets

242,199

265,352

41,859

Total current assets

2,801,737

2,687,791

423,990

Property and equipment

80,254

77,582

12,238

Intangible assets

4,909

4,472

705

Long-term investments

3,000

2,000

315

Other non-current assets

22,086

22,217

3,505

Operating lease right-of-use asset

233,847

217,300

34,278

Total Assets

3,145,833

3,011,362

475,031

LIABILITIES AND EQUITY

Current Liabilities:

Short-term borrowings

259,658

259,592

40,950

Accounts payable

1,347,352

1,366,777

215,602

Accrued expenses and other current liabilities

522,968

454,637

71,718

Total Current liabilities

2,129,978

2,081,006

328,270

Long-term operating lease liabilities

165,614

152,642

24,079

Other non-current liabilities

1,537

987

156

Total Liabilities

2,297,129

2,234,635

352,505

MEZZANINE EQUITY

Redeemable non-controlling interests

1,000,849

1,014,680

160,062

SHAREHOLDERS' DEFICIT

Ordinary shares Class A

31

31

5

Ordinary shares Class B

25

25

4

Treasury shares

(40,859)

(40,859)

(6,445)

Additional paid-in capital

2,817,789

2,847,793

449,228

Accumulated deficit

(3,009,678)

(3,120,021)

(492,171)

Accumulated other comprehensive income

59,371

58,378

9,209

Total shareholders' deficit

(173,321)

(254,653)

(40,170)

Non-controlling interest

21,176

16,700

2,634

Total Deficit

(152,145)

(237,953)

(37,536)

Total liabilities,mezzanine equity and deficit

3,031

111,Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands,except for share and per share data)

For the three months ended March 31,

2021

2022

RMB

RMB

US$

Net Revenues

2,594,742

2,982,591

470,492

Operating Costs and expenses:

Cost of products sold

(2,478,972)

(2,790,056)

(440,121)

Fulfillment expenses

(66,255)

(94,533)

(14,912)

Selling and marketing expenses

(122,428)

(114,854)

(18,118)

General and administrative expenses

(52,137)

(47,994)

(7,571)

Technology expenses

(49,698)

(39,021)

(6,155)

Other operating income,net

1,483

1,716

271

Total Operating costs and expenses

(2,768,007)

(3,084,742)

(486,606)

Loss from operations

(173,265)

(102,151)

(16,114)

Interest income

3,115

2,043

322

Interest expense

(1,813)

(3,184)

(502)

Foreign exchange (loss) gain

(511)

391

62

Other Income,net

2,991

1,913

302

Loss before income taxes

(169,483)

(100,988)

(15,930)

Income tax expense

-

-

-

Net Loss

(169,930)

Net Loss attributable to non-controlling interest

22,843

4,477

706

Net Loss attributable to redeemable non-controlling interest

-

9,135

1,441

Adjustment attributable to redeemable non-controlling interest

-

(22,966)

(3,623)

Net Loss attributable to ordinary shareholders

(146,640)

(110,342)

(17,406)

Other comprehensive income (loss),net of tax of nil

Unrealized gains of available-for-sale securities

2,358

1,298

205

Realized gains of available-for-sale securities

(2,441)

(1,335)

(211)

Foreign currency translation adjustments

1,705

(956)

(151)

Comprehensive loss

(145,018)

(111,335)

(17,563)

Loss per share:

Basic and diluted

(0.89)

(0.66)

(0.10)

Loss per ADS:

Basic and diluted

(1.78)

(1.32)

(0.20)

Weighted average number of shares used in computation of loss per share

Basic and diluted

165,587,950

166,331,126

166,126

111,Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

For the three months ended March 31,

2021

2022

RMB

RMB

US$

Net cash used in operating activities

(259,430)

(68,241)

(10,765)

Net cash provided by investing activities

85,498

22,859

3,606

Net cash (used in) provided by financing activities

(182,820)

35,278

5,565

Effect of exchange rate changes on cash and cash equivalents,and restricted cash

1,194

(731)

(115)

Net decrease in cash and cash equivalents,and restricted cash

(355,558)

(10,835)

(1,709)

Cash and cash equivalents,and restricted cash at the beginning of the period

1,318,534

760,672

119,993

Cash and cash equivalents,and restricted cash at the end of the period

962,976

749,837

118,284

111,Inc.

Unaudited Reconciliation of GAAP and Non-GAAP Results

For the three months ended March 31,

2021

2022

RMB

RMB

US$

Loss from operations

(173,265)

(102,151)

(16,114)

Add: Share-based compensation expenses

37,377

29,757

4,694

Non-GAAP loss from operations

(135,888)

(72,394)

(11,420)

Net Loss

(169,483)

(100,988)

(15,930)

Add: Share-based compensation expenses,net of tax

37,694

Non-GAAP net Loss

(132,106)

(71,231)

(11,236)

Net loss attributable to ordinary shareholders

(146,640)

(110,342)

(17,406)

Add: Share-based compensation expenses,694

Non-GAAP net loss attributable to ordinary shareholders

(109,263)

(80,585)

(12,712)

Loss per ADS: Basic and diluted

(1.78)

(1.32)

(0.20)

Add: Share-based compensation expenses per ADS,net of tax

0.45

0.36

0.06

Non-GAAP Loss per ADS

(1.33)

(0.96)

(0.14)

View original content:https://www.prnewswire.com/news-releases/111-inc-announces-first-quarter-2022-unaudited-financial-results-301569343.html